Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide in Relapsed or Refractory Low Grade Non-Hodgkin's Lymphoma
NCT00022581Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2001
- Primary completion
- Dec 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thalidomide in non-Hodgkin lymphoma (NHL), sponsored by National Cancer Institute. Primary endpoints: Response Rate up to 5 years, Time to Progression up to 5 years and 2 more. Started Jul 2001; status: completed.
02
Drugs
thalidomide
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00022581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00022581.